Cognition Thought Leadership

Conversations: Fireside Video Chats

The new “Conversations” video series will feature virtual fireside chats with neuroscience experts who will discuss advances in the research and treatment of Alzheimer’s disease, dementia with Lewy bodies (DLB), and other age-related neurodegenerative conditions. Please use the form at the bottom of our webpage you submit your comments or feedback.

Episode 2: Building on Amyloid Lowering: Key Insights from Recent Data and Prospects for Complementary Therapeutic Approaches

Featuring:
Anthony Caggiano, M.D., Ph.D. Cognition’s Chief Medical Officer and Head of R&D Episode 1 thumbnail
Christopher H. van Dyck, M.D. Yale University School of Medicine Professor of Psychiatry, Neurology, and Neuroscience; Director of the Yale School of Medicine Division of Aging and Geriatric Psychiatry; and Director of the Alzheimer’s Disease Research Center
Anton P. Porsteinsson, M.D. University of Rochester School of Medicine and Dentistry William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine; and Director of the Alzheimer’s Disease Care, Research and Education Program (AD-CARE)
Episode 1: Dementia with Lewy Bodies
Featuring:
Anthony Caggiano, M.D., Ph.D. Cognition’s Chief Medical Officer and Head of R&D Episode 1 thumbnail
James Galvin, M.D., MPH Director of the Comprehensive Center for Brain Health
University of Miami Miller School of Medicine
Principal investigator of the SHIMMER clinical trial

Leadership Editorials

By Lisa Ricciardi
October 1, 2022

Questions? Send us an email:

Social Media

Major validation in @NEJM of our approach at @CogRx protecting brain cells from toxic #oligomers. Decades of work into #amyloid paying off, as researchers now target oligomers as key neurotoxin. Moving the needle for #AlzheimersDisease patients. https://www.nejm.org/doi/full/10.1056/NEJMe2214981 $CGTX

The 2nd episode of the “Conversations” video podcast, featuring Dr. C Van Dyck of @YaleMed and Dr. A Porsteinsson of #UnivofRochester @urmc_psych is available online now. https://cogrx.com/conversations/ #Alzheimers #dementia #clinicalresearch http://bit.ly/3PKs5d8

Cognition mgmt will conduct one-on-one meetings with investors and pharmaceutical companies during the annual #Sachs_NIF and #BiotechShowcase2023 conferences during the iconic #JPM23 Week in #SanFrancisco. #biotech #Alzheimers #dementia. http://bit.ly/3jgVsHT

The @brc_onderzoek has dosed the first participant in Europe in our recently expanded Phase 2 SHINE of CT1812 for mild-to-moderate #Alzheimers disease

#dementia #clincialtrials #clinicalresearch http://bit.ly/3YnKMY2

Load More
Scroll to Top
Scroll to Top

You are now leaving the Cognition Therapeutics website

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.